Mereo BioPharma Group plc

NASDAQ:MREO

Biotechnology

Healthcare
$0.32 +9.69%

+$0.03 today

Market cap
$51.08M
Beta
0.28
P/E (TTM)
-1.4
EPS (TTM)
-$0.22
52W Low $0.20High $3.05

Volume 1.26M

Average 3.36M

MREO Net Change in Cash

Combined operating, investing, financing, and currency effects on the cash balance during the period.

Mereo BioPharma Group plcNASDAQ: MREO

Net Change in Cash · Q1 FY2026 · quarter ended Mar 2026

Net change in cash declines year over year

Q1 FY2026 net change in cash of $4.77M (cash outflow) fell 34.8% year over year, ahead of the -290.0% change in trailing-twelve-month net change in cash. Sequentially, it fell 38.1% from the prior quarter. Over 3 fiscal years it compounded at -21.3% a year.

Context

  • Net change in cash amounted to 5762.0% of revenue in FY2025.
  • Net change in cash increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -34.8% holds above the trailing-twelve-month pace of -290.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$4.77M-38.1% QoQ
Last fiscal yearDec 2025
-$28.81M-332.7% YoY
LTMMar 2026
-$26.26M-290.0% YoY
Net Change in Cash past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-34.8%——
1 year-332.7%——
3-year CAGR-21.3%——
5-year CAGR——
10-year CAGR——

Net Change in Cash history

USD · from the cash flow

Latest · FY2025
(28.81M) USD
Year-over-year change
-332.7%

Net Change in Cash vs competitors

How MREO compares with its peers on the latest reported figures

  • Peers report in different currencies, so net change in cash is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -290.0% is the 9th highest of 10, against a peer median of -77.8%.
  • Net change in cash amounts to 5252.0% of revenue for MREO, versus a peer median of 1133.4%.
MREO Competitors
Net Change in Cash for MREO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CADLCandel Therapeutics, Inc.LTM Mar 2026$102.82M USD+54.7%——
IMMPImmutep LimitedFY2025A$94.38M AUD-346.0%—1871.3%
CAPRCapricor Therapeutics, Inc.LTM Mar 2026$76.63M USD+239.4%——
SLNSilence Therapeutics plcLTM Mar 2026$59.21M USD—+49.3%6425.7%
PRQRProQR Therapeutics N.V.LTM Mar 2026€53.17M EUR-213.8%-24.9%395.5%
LXEOLexeo Therapeutics, Inc. Common StockLTM Mar 2026$42.86M USD+125.8%——
MREOMereo BioPharma Group plcLTM Mar 2026$26.26M USD-290.0%-21.3%5252.0%
KYTXKyverna Therapeutics, Inc.LTM Mar 2026$24.68M USD-85.3%——
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$14.65M USD+134.8%——
ACIUAC Immune S.A.LTM Dec 2025CHF 9.36M CHF-77.8%-54.0%262.0%
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 2026$2.31M USD-137.3%+285.2%—
Peer median (excluding MREO) —-77.8%+12.2%1133.4%

Competitors are the stored peer set for MREO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income19.22M(42.22M)(29.47M)(43.25M)(41.88M)
Depreciation & Amortization866.47K889K1.06M1.09M622K
Deferred Income Tax00000
Stock-Based Compensation4.46M4.77M4.92M7.39M7.6M
Change in Working Capital(2.49M)(2.35M)(1.59M)(369K)(3.21M)
Accounts Receivables(794.94K)(3.47M)456K(1.65M)1.4M
Inventory00000
Accounts Payables0617K(1.26M)146K(1.38M)
Other Working Capital(1.7M)498K(786K)1.13M(3.23M)
Other Non-Cash Items(29.12M)(9.91M)3.94M2.31M5.9M
Operating Cash Flow(7.07M)(48.82M)(21.13M)(32.83M)(30.97M)
Capital Expenditures(722.06K)(13K)(419K)(699K)(20K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities153.86K2M(419K)00
Investing Cash Flow(568.2K)1.99M(419K)(699K)(20K)
Debt Repayment(933.95K)0(3.19M)00
Common Stock Issued105.99M011.61M47M327.76K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(253.73K)200K24K(853K)(764)
Financing Cash Flow104.8M200K7.97M46.15M327K
Effect of Forex Changes(1.57M)(12.58M)2.82M(233K)1.93M
Net Change in Cash95.59M(59.22M)(10.76M)12.38M(28.81M)
Free Cash Flow(7.79M)(48.83M)(21.55M)(33.53M)(30.99M)

Mereo BioPharma Group plc

NASDAQ:MREO

Intrinsic Alpha fair value

Locked

Current Price

$0.32

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.